Literature DB >> 24627481

Glycosylphosphatidylinositol anchoring directs the assembly of Sup35NM protein into non-fibrillar, membrane-bound aggregates.

Karen E Marshall1, Danielle K Offerdahl, Jonathan O Speare, David W Dorward, Aaron Hasenkrug, Aaron B Carmody, Gerald S Baron.   

Abstract

In prion-infected hosts, PrPSc usually accumulates as non-fibrillar, membrane-bound aggregates. Glycosylphosphatidylinositol (GPI) anchor-directed membrane association appears to be an important factor controlling the biophysical properties of PrPSc aggregates. To determine whether GPI anchoring can similarly modulate the assembly of other amyloid-forming proteins, neuronal cell lines were generated that expressed a GPI-anchored form of a model amyloidogenic protein, the NM domain of the yeast prion protein Sup35 (Sup35(GPI)). We recently reported that GPI anchoring facilitated the induction of Sup35(GPI) prions in this system. Here, we report the ultrastructural characterization of self-propagating Sup35(GPI) aggregates of either spontaneous or induced origin. Like membrane-bound PrPSc, Sup35(GPI) aggregates resisted release from cells treated with phosphatidylinositol-specific phospholipase C. Sup35(GPI) aggregates of spontaneous origin were detergent-insoluble, protease-resistant, and self-propagating, in a manner similar to that reported for recombinant Sup35NM amyloid fibrils and induced Sup35(GPI) aggregates. However, GPI-anchored Sup35 aggregates were not stained with amyloid-binding dyes, such as Thioflavin T. This was consistent with ultrastructural analyses, which showed that the aggregates corresponded to dense cell surface accumulations of membrane vesicle-like structures and were not fibrillar. Together, these results showed that GPI anchoring directs the assembly of Sup35NM into non-fibrillar, membrane-bound aggregates that resemble PrPSc, raising the possibility that GPI anchor-dependent modulation of protein aggregation might occur with other amyloidogenic proteins. This may contribute to differences in pathogenesis and pathology between prion diseases, which uniquely involve aggregation of a GPI-anchored protein, versus other protein misfolding diseases.

Entities:  

Keywords:  Amyloid; Electron Microscopy (EM); Glycosylphosphatidylinositol Anchors; Prions; Protein Aggregation; Protein Misfolding; Protein Self-assembly

Mesh:

Substances:

Year:  2014        PMID: 24627481      PMCID: PMC4007424          DOI: 10.1074/jbc.M114.556639

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  89 in total

1.  The relationship between visible intracellular aggregates that appear after overexpression of Sup35 and the yeast prion-like elements [PSI(+)] and [PIN(+)].

Authors:  P Zhou; I L Derkatch; S W Liebman
Journal:  Mol Microbiol       Date:  2001-01       Impact factor: 3.501

Review 2.  Review: history of the amyloid fibril.

Authors:  J D Sipe; A S Cohen
Journal:  J Struct Biol       Date:  2000-06       Impact factor: 2.867

3.  Highly sensitive diagnosis of amyloid and various amyloid syndromes using Congo red fluorescence.

Authors:  R P Linke
Journal:  Virchows Arch       Date:  2000-05       Impact factor: 4.064

4.  The protofilament substructure of amyloid fibrils.

Authors:  L C Serpell; M Sunde; M D Benson; G A Tennent; M B Pepys; P E Fraser
Journal:  J Mol Biol       Date:  2000-07-28       Impact factor: 5.469

5.  Evidence for the prion hypothesis: induction of the yeast [PSI+] factor by in vitro- converted Sup35 protein.

Authors:  H E Sparrer; A Santoso; F C Szoka; J S Weissman
Journal:  Science       Date:  2000-07-28       Impact factor: 47.728

6.  Prions affect the appearance of other prions: the story of [PIN(+)].

Authors:  I L Derkatch; M E Bradley; J Y Hong; S W Liebman
Journal:  Cell       Date:  2001-07-27       Impact factor: 41.582

7.  Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain.

Authors:  W E Klunk; Y Wang; G F Huang; M L Debnath; D P Holt; C A Mathis
Journal:  Life Sci       Date:  2001-08-17       Impact factor: 5.037

8.  Nucleated conformational conversion and the replication of conformational information by a prion determinant.

Authors:  T R Serio; A G Cashikar; A S Kowal; G J Sawicki; J J Moslehi; L Serpell; M F Arnsdorf; S L Lindquist
Journal:  Science       Date:  2000-08-25       Impact factor: 47.728

9.  In vivo detection of amyloid plaques in a mouse model of Alzheimer's disease.

Authors:  D M Skovronsky; B Zhang; M P Kung; H F Kung; J Q Trojanowski; V M Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-20       Impact factor: 11.205

10.  Prion filament networks in [URE3] cells of Saccharomyces cerevisiae.

Authors:  V V Speransky; K L Taylor; H K Edskes; R B Wickner; A C Steven
Journal:  J Cell Biol       Date:  2001-06-11       Impact factor: 10.539

View more
  4 in total

1.  Prion protein post-translational modifications modulate heparan sulfate binding and limit aggregate size in prion disease.

Authors:  Julia A Callender; Alejandro M Sevillano; Katrin Soldau; Timothy D Kurt; Taylor Schumann; Donald P Pizzo; Hermann Altmeppen; Markus Glatzel; Jeffrey D Esko; Christina J Sigurdson
Journal:  Neurobiol Dis       Date:  2020-05-24       Impact factor: 5.996

2.  PrP Knockout Cells Expressing Transmembrane PrP Resist Prion Infection.

Authors:  Karen E Marshall; Andrew Hughson; Sarah Vascellari; Suzette A Priola; Akikazu Sakudo; Takashi Onodera; Gerald S Baron
Journal:  J Virol       Date:  2017-01-03       Impact factor: 5.103

3.  Dissociation of recombinant prion autocatalysis from infectivity.

Authors:  Geoffrey P Noble; Surachai Supattapone
Journal:  Prion       Date:  2015       Impact factor: 3.931

4.  A Structural and Functional Comparison Between Infectious and Non-Infectious Autocatalytic Recombinant PrP Conformers.

Authors:  Geoffrey P Noble; Daphne W Wang; Daniel J Walsh; Justin R Barone; Michael B Miller; Koren A Nishina; Sheng Li; Surachai Supattapone
Journal:  PLoS Pathog       Date:  2015-06-30       Impact factor: 6.823

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.